This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rozzini, L. Articles by Padovani, A. Search for Related Content PubMed PubMed Citation Articles by Rozzini, L. Articles by Padovani, A. Social Bookmarking                         What's this?

Cognitive and Psychopathologic Response to Rivastigmine in Dementia With Lewy Bodies Compared to Alzheimer’s Disease: A Case Control Study

Department of Neurology, University of Brescia, Geriatric Research Group, Brescia, Italy, lrozzini{at}iol.it

Barbara Vicini Chilovi, MD

Department of Neurology, University of Brescia, Geriatric Research Group, Brescia, Italy

Erik Bertoletti, MD

Department of Neurology, University of Brescia, Italy

Marta Conti, MD

Department of Neurology, University of Brescia, Italy

Ilenia Delrio, MD

Department of Neurology, University of Brescia, Italy

Marco Trabucchi, MD, PhD

Geriatric Research Group, Brescia, Italy

Alessandro Padovani, MD, PhD

Department of Neurology, University of Brescia, Italy

Cholinesterase inhibitors (ChEIs) are effective in improving cognition and behavior in patients affected by Alzheimer’s disease (AD) as well as by Lewy bodies dementia (DLB). The authors compared the effect of rivastigmine in the treatment of cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) in 30 AD and in 30 DLB patients. At baseline, DLB compared to AD patients showed a greater number of extrapyramidal symptoms (P < .005) and were similar regarding cognitive symptoms and BPSD. After treatment, both groups showed a comparable cognitive and psycho-behavioral improvement. A significant difference between AD and DLB patients was found for hallucinations (P < .002). Rivastigmine produces comparable cognitive benefits in patients with DLB and AD and also a significant improvement of behavioral disorders. These findings support the view that ChEIs should be considered a first-line treatment of the cognitive and psycho-behavioral symptoms of both AD and DLB.

Key Words: Alzheimer’s disease • dementia with Lewy bodies • cholinesterase inhibitors • BPSD

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 22, No. 1, 42-47 (2007)
DOI: 10.1177/1533317506297517


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. E. Lancioni, N. N. Singh, M. F. O'Reilly, J. Sigafoos, M. T. Pangrazio, M. Megna, N. Zonno, M. L. La Martire, K. Pinto,, and M. G. Minervini Persons With Moderate Alzheimer's Disease Improve Activities and Mood via Instruction Technology American Journal of Alzheimer's Disease and Other Dementias, June 1, 2009; 24(3): 246 - 257. [Abstract] [PDF]

				G. E. Lancioni, M. L. La Martire, N. N. Singh, M. F. O'Reilly, J. Sigafoos, K. Pinto, and M. G. Minervini Persons With Mild or Moderate Alzheimer's Disease Managing Daily Activities via Verbal Instruction Technology American Journal of Alzheimer's Disease and Other Dementias, January 1, 2009; 23(6): 552 - 562. [Abstract] [PDF]